Insmed (INSM) Misses Q2 EPS by 65c, beats revenue, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $94.28 +0.26%
EPS Growth %: +77.7%
Financial Fact:
Interest expense: -769K
Today's EPS Names:
SICP, MNSB, CFFI, More
EPS Growth %: +77.7%
Financial Fact:
Interest expense: -769K
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q2 EPS of ($1.78), $0.65 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $77.2 million versus the consensus estimate of $71.01 million.
Guidance:
Insmed is raising its sales guidance for full-year 2023 global revenues for ARIKAYCE to a range of $295 million to $305 million from a range of $285 million to $300 million previously.
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- JetBlue shares fall amid American results, fuel cost concerns
- Comcast third-quarter earnings top estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
